A genome-wide CRISPR screen revealed that loss of general control nonderepressible 2 (GCN2) kinase increases cellular resistance to the pan-ErbB inhibitor neratinib with neratinib directly binding and activating GCN2 kinase activity.
- Colin P. Tang
- Owen Clark
- Ingo K. Mellinghoff